Palvella Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Wesley H. Kaupinen
- Full Time Employees
- 29
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 353 W. Lancaster Avenue Wayne PA United States of America 19087
- IPO Date
- Jan 2, 2015
- CIK
- 0001583648
- Website
- palvellatx.com
- Similar Companies
- Business
- Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of novel therapies for patients with serious, rare genetic skin diseases, particularly those lacking FDA-approved treatments. The company’s main product portfolio centers around QTORIN™, a platform of topical treatments that includes QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin. QTORIN™ rapamycin is developed for the treatment of microcystic lymphatic malformations (LMs), cutaneous venous malformations (VMs), and clinically significant angiokeratomas, diseases driven by overactivation of the mTOR pathway. QTORIN™ pitavastatin targets disseminated superficial actinic porokeratosis (DSAP), a rare, chronic, precancerous genetic skin disorder with no approved therapies. The company’s clinical development is advancing with QTORIN™ rapamycin in a Phase 3 SELVA trial for microcystic LMs and a Phase 2 study for cutaneous VMs, with topline results expected in late 2025 and early 2026. Additionally, Palvella plans to initiate a Phase 2 trial for angiokeratomas in 2026. The QTORIN™ pitavastatin candidate was announced in late 2025, marking a significant expansion of the pipeline to address four distinct rare skin diseases. Palvella’s pipeline expansion underscores its strategic focus on rare dermatological conditions with high unmet medical needs. Significant recent corporate developments include the completion of a merger with Pieris Pharmaceuticals in December 2024, which was accompanied by a private placement financing totaling $78.9 million. This capital infusion supports ongoing clinical programs and operations through at least the second half of 2027. The company is simultaneously building out commercial and medical affairs teams in preparation for potential U.S. commercialization in 2027, reflecting a strategic transition towards commercial readiness. Founded in 2015, Palvella Therapeutics is headquartered in Wayne, Pennsylvania, and operates primarily in the United States. Its leadership team has a committed focus on advancing targeted treatments for rare genodermatoses. Palvella’s therapeutic programs leverage proprietary formulations designed to optimize topical delivery of mTOR inhibitors and other agents to affected skin tissues, aiming to offer first-in-class or best-in-class solutions for patients with serious dermatologic conditions. Overall, Palvella Therapeutics operates in the biotechnology sector within the healthcare industry, targeting niche markets of rare skin diseases with unmet clinical needs. The company’s focused product development, recent merger and financing activities, and clinical advancements position it as a clinically promising rare disease biopharmaceutical entity with a growing pipeline of innovative dermatological therapies.
Company News
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics Appoints James R. Treat, M.D.
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Bank of America Corp DE Has $4.73 Million Holdings in Palvella Therapeutics, Inc. $PVLA
Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
Palvella Therapeutics Q2 Earnings Call Highlights
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Palvella Therapeutics Q2 Earnings Call Highlights
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
Fifth Third Bancorp Invests $2.49 Million in Palvella Therapeutics, Inc. $PVLA
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors